Orca Bio looks to increase its cell therapy manufacturing capacity with a new facility in Sacramento
While Orca Bio has netted some major milestones, such as a $192 million Series D and a regenerative medicine advanced therapy (RMAT) designation from the FDA, the company is looking to step up things on the manufacturing side of the business.
Orca Bio will expand its manufacturing capabilities by constructing a new 100,000-square-foot commercial facility in Sacramento, CA.
In an interview with Endpoints News, Orca Bio COO Jeroen Bekaert said the biotech is now evolving into a late-stage cell therapy company and is starting its Phase III with the Orca-T product, which has increased their need for manufacturing space.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.